Nippon Shinyaku Co., Ltd. (JP:4516)
:4516
Want to see JP:4516 full AI Analyst Report?
4516 Stock Chart & Stats
¥5650.00
-¥42.00(-1.04%)
At close: 4:00 PM EST
¥5650.00
-¥42.00(-1.04%)
Day’s Range― - ―
52-Week Range¥2,967.00 - ¥6,529.00
Previous CloseN/A
Volume198.40K
Average Volume (3M)252.03K
Market Cap
¥273.12B
Enterprise Value¥209.13B
Total Cash (Recent Filing)¥76.59B
Total Debt (Recent Filing)¥2.57B
Price to Earnings (P/E)9.2
Beta0.33
Next Earnings
Aug 11, 2026EPS Estimate
124.6Next Dividend Ex-DateN/A
Dividend Yield2.12%
Share Statistics
EPS (TTM)441.04
Shares Outstanding70,251,490
10 Day Avg. Volume218,840
30 Day Avg. Volume252,026
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)1.18
Price to Sales (P/S)2.02
P/FCF Ratio14.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,200.00Price Target Upside-7.96% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)400.64
Revenue Forecast (FY)¥189.20B
Bulls Say, Bears Say
Bulls Say
High Margin ProfileSustained high gross and operating margins indicate durable pricing power and a capital-light product mix typical of specialty pharmaceuticals. This margin cushion supports long-term R&D funding, lifecycle investments, and resilience to cost swings, preserving core profitability over time.
Very Conservative Balance SheetExtremely low leverage provides meaningful financial flexibility: capacity to fund acquisitions, R&D, or defend against reimbursement headwinds without forcing dilutive financing. A fortress balance sheet materially reduces solvency risk and supports multi-year strategic plans.
Strong Cash Conversion And Steady Top-lineHigh cash conversion and consistent revenue expansion mean internal funding for development and shareholder returns is sustainable. Reliable FCF relative to earnings supports reinvestment, dividend policy, and reduces dependence on external capital over the medium term.
Bears Say
Recent Margin And Profit PressureA material step-down in margins and operating profit signals emerging cost, mix, or investment pressures that could persist. If structural (e.g., higher SG&A or escalating launch costs), sustained margin erosion would constrain reinvestment capacity and long-term earnings durability.
Volatile Cash Flow GenerationNotable FCF decline and weaker operating cash flow indicate working-capital swings or higher near-term investment needs. Persistent cash volatility can impair predictable funding for R&D/dividends and force trade-offs in capital allocation, weakening long-run financial planning.
Declining Return On EquityA falling ROE reflects reduced capital efficiency from softer profits or a larger equity base. If sustained, lower ROE can signal diminished investment returns and may limit the company's ability to deliver attractive shareholder value versus peers over multiple years.
Nippon Shinyaku Co., Ltd. News
4516 FAQ
What was Nippon Shinyaku Co., Ltd.’s price range in the past 12 months?
Nippon Shinyaku Co., Ltd. lowest stock price was ¥2967.00 and its highest was ¥6529.00 in the past 12 months.
What is Nippon Shinyaku Co., Ltd.’s market cap?
Nippon Shinyaku Co., Ltd.’s market cap is ¥273.12B.
When is Nippon Shinyaku Co., Ltd.’s upcoming earnings report date?
Nippon Shinyaku Co., Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.
How were Nippon Shinyaku Co., Ltd.’s earnings last quarter?
Nippon Shinyaku Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥57.5 earnings per share for the quarter, missing the consensus estimate of ¥69.25 by -¥11.75.
Is Nippon Shinyaku Co., Ltd. overvalued?
According to Wall Street analysts Nippon Shinyaku Co., Ltd.’s price is currently Overvalued.
Does Nippon Shinyaku Co., Ltd. pay dividends?
Nippon Shinyaku Co., Ltd. pays a Semiannually dividend of ¥62 which represents an annual dividend yield of 2.12%. See more information on Nippon Shinyaku Co., Ltd. dividends here
What is Nippon Shinyaku Co., Ltd.’s EPS estimate?
Nippon Shinyaku Co., Ltd.’s EPS estimate is 124.6.
How many shares outstanding does Nippon Shinyaku Co., Ltd. have?
Nippon Shinyaku Co., Ltd. has 70,251,490 shares outstanding.
What happened to Nippon Shinyaku Co., Ltd.’s price movement after its last earnings report?
Nippon Shinyaku Co., Ltd. reported an EPS of ¥57.5 in its last earnings report, missing expectations of ¥69.25. Following the earnings report the stock price went up 2.915%.
Which hedge fund is a major shareholder of Nippon Shinyaku Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4516
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
4516 Stock 12 Month Forecast
Average Price Target
¥5,200.00
▼(-7.96% Downside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Toho Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---